Chiusura precedente | 7,45 |
Aperto | 7,44 |
Denaro | 5,28 x 200 |
Lettera | 9,48 x 200 |
Min-Max giorno | 7,31 - 7,45 |
Intervallo di 52 settimane | 7,11 - 15,49 |
Volume | |
Media Volume | 35.291 |
Capitalizzazione | 179,552M |
Beta (5 anni mensile) | 0,79 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,35 |
Prossima data utili | 09 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 12,61 |
TORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its Analyst & Investor Day event scheduled for Friday, October 13, 2023. The agenda will commence at 1:00 p.m. and is scheduled to conclude at approximately 3:30 p.m. Eastern Time. The program
The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsuleTORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA) for the Company’s T
TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host an Analyst & Investor Day event on Friday, October 13, 2023 from 1:00 p.m. to approximately 3:30 p.m. Eastern Time. “The program will feature presentations on TULSA-PRO® and its unrivalled flexibility to treat a wide variety o